That’s why I’m taking my new medal out for a spin and urging America’s elected leaders to do everything in their power to end Parkinson’s once and for all. Need a break? Play the USA ...

Parkinson’s disease, which is lifelong ... through its $8.7 billion purchase of Cerevel Therapeutics last year. In other late-stage trials, tavapadon showed improvement of symptom control ...

Parkinson's disease is an illness that affects the part of your brain that controls how you move your body. Some people with Parkinson’s first notice weakness, difficulty walking, and stiff muscles.

Mark Giaquinto was diagnosed with Parkinson's disease five years ago and continues to combat the illness with a positive outlook.

Roche and partner Prothena are currently the furthest ahead in the field, after starting a phase 2b trial of their prasinezumab candidate in patients with early-stage Parkinson's last year ...

treatment with tavapadon as a monotherapy in adults with early Parkinson's disease. Also Read: Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of ...

A decline in motor skills is a hallmark of Parkinson's disease, regularly taking the form ... in getting it to penetrate into the brain and last for longer. While these are promising results ...

Roche said a Parkinson's disease experimental drug missed its primary goal in a mid-stage trial, the second setback this week for candidate treatments for the neurodegenerative condition.

Parkinson’s disease affects [mostly] dopaminergic ... The data that should be available by mid-2025 may also set the stage for final partnership or acquisition negotiations.